November 14: ECF - Annual Meeting 2025

08:00 08:30	ACTRIMS Lecture
08:30 10:00	SESSION III — Addressing progression by BTK Inhibition: Hype or Hope? Chair: Krzysztof Selmaj
08:30 08:50	Molecular mechanisms of action and differences between them	Diego Centonze
08:30 09:10	Clinical data and on going clinical trials	Xavier Montalban
09:10 09:30	Target patient profile and safety concerns	Jiwon Oh
09:30 09:50	Industry panel: Future of BTKis Roche, Sanofi, Merck, Biogen, Novartis (1 speaker for each pharma company + lead investigator)	Moderator Ludwig Kappos
09:50 10:00	Q&A
10:00 10:30	Coffee Break & Poster Viewing

10:30 12:00	SESSION IV — More aggressive B-cell depletion or a dual effect? Chair: Hans Peter Hartung
10:30 10:50	AntiCD20 moab: dosing and safety issues	Fredrik Piehl
10:50 11:10	Basics of CAR T-cell therapy	Barbara Willekens
11:10 11:30	CAR T-Cell Therapy in MS and related disorders	Manuel Friese
11:30 11:50	Biomarkers in progressive MS	Patrick Vermersch
11:50 12:00	Q&A
12:00 13:00	Satellite Symposium – MERCK
13:00 14:00	Light Lunch & Poster Viewing

14:00 15:30	SESSION V — New and emerging Therapies in NMOSD & MOGAD Chair: Jaqueline Palace
14:00 14:20	Difference in pathology and inflammatory mechanisms between MS, MOGAD and NMOSD; consequences for therapy	Romana Höftberger
14:20 14:40	Complement inhibitors (eculizumab, ravulizumab)	Romain Marignier
14:40 15:00	TB-Cell depleting and IL-6 receptor inhibition therapies	Paul Friedemann
15:00 15:20	Other Investigational Molecules	Michael Yeaman
15:20 15:30	Q&A
15:30 17:00	SESSION VI — Anti-viral strategies Chair: Sandra Vukusic
15:30 15:50	Anti viral effects of approved MS drugs (EBV)	Marco Salvetti
15:50 16:10	Emerging new antiviral treatment strategies in MS	Gavin Giovannoni
16:10 16:30	Targeting HERV-w env	Patrick Küry
16:30 16:50	Vaccination in MS patients	Susanna Otero
16:50 17:00	Q&A

Time	Programme	Speaker
08:00 - 08:30	ACTRIMS Lecture	Mark Freedman
08:30 - 10:00 08:30 - 08:50 08:50 - 09:10 09:10 - 09:30 09:30 - 09:50 09:50 - 10:00	SESSION III — Addressing progression by BTK Inhibition: Hype or Hope? Chair: Krzysztof Selmaj Molecular mechanisms of action and differences between them --- Clinical data and on going clinical trials --- Target patient profile and safety concerns --- Industry panel: Future of BTKis Roche, Sanofi, Merck, Novartis (1 speaker for each pharma company + lead investigator) --- Q&A	Joao Cerqueira Xavier Montalban Jiwon Oh Moderator Ludwig Kappos
10:00 - 10:30	Coffee Break & Poster Viewing
10:30 - 12:00 10:30 - 10:50 10:50 - 11:10 11:10 - 11:30 11:30 - 11:50 11:50 - 12:00	SESSION IV — More aggressive B-cell depletion or a dual effect? Chair: Maria Trojano AntiCD20 moab: dosing and safety issues --- Basics of CAR T-cell therapy --- CAR T-Cell Therapy in MS and related disorders --- Frexalimab and CD40L blockade --- Q&A	Fredrik Piehl Barbara Willekens Hans Peter Hartung Patrick Vermersch
12:00 - 13:00	Satellite Symposium - MERCK
13:00 - 14:00	Light Lunch & Poster Viewing
14:00 - 15:30 14:00 - 14:20 14:20 - 14:40 14:40 - 15:00 15:00 - 15:20 15:20 - 15:30	SESSION V — New and emerging Therapies in NMOSD & MOGAD Chair: Jacqueline Palace Difference in pathology and inflammatory mechanisms between MS, MOGAD and NMOSD; consequences for therapy --- Complement inhibitors (eculizumab, ravulizumab) --- B-Cell depleting and IL-6 receptor inhibition therapies --- Other Investigational Molecules --- Q&A	Hans Lassmann Romain Marignier Paul Friedemann TBC
15:30 - 17:00 15:30 - 15:50 15:50 - 16:10 16:10 - 16:30 16:30 - 16:50 16:50 - 17:00	SESSION VI — Anti-viral strategies Chair: Sandra Vukusic Anti viral effects of approved MS drugs (EBV) --- Emerging new antiviral treatment strategies in MS --- Targeting HERV-w env --- Vaccination in MS patients --- Q&A	Marco Salvetti Gavin Giovannoni Patrick Küry Susana Otero
17:00 - 17:20	Coffee Break
17:20 - 18:20	Satellite Symposium - BMS
18:20 - 18:30	Announcement Young Investigator Award Winners
18:30 - 19:30	Satellite Symposium - SANDOZ